Nautilus GmbH Laboratoriumsbedarf & Co. KG

*Among long COVID symptoms. The experimental chewing gum traps the SARS-CoV-2 particles in saliva holds promise for curbing transmission of new variants of the virus, according to new data, as researchers prepare to launch the first human trial.

Calcium-3-Phytosterol is an FDA-approved Cholesterol-lowering Nutraceutical, a proprietary, patent-pending water soluble calcium rich nutraceutical ingredient incorporating the proven medical benefits of cholesterol-lowering plant sterols.

A Newly Developed Designer Nicotine Beverage May Help Smoker's Curb Nicotine Cravings

In January 2003, the Swiss firm NicStic AG filed for a patent on a product that could represent a quantum leap for smokers; a cigarette that is not only low in nicotine, but is actually smoke free.

One of the oldest condiments in the world, "soy sauce" discovered in China more than 2,500 years ago, is getting a new stimulating makeover with "Kamikaze" Caffeinated Soy Sauce.

Richard H. Davis, President and CEO of Nautilus GmbH Laboratoriumsbedarf & Co. KG., states that his company intends to produce and market an advanced smoking-cessation bottled water; "Nicotine Water".

Nautilus GmbH Laboratoriumsbedarf & Co. KG, recently announced the launch of its new patent-pending xanthohumol supplement called BierMax™, during the Oktoberfest celebration. Each BierMax capsule contains 333 mg.

While NicoShot can lessen cravings, it is not a 'cure' for smoking. But it can help you make changes in your lifestyle without having to walk out of the bar for a quick smoke to deal with sudden withdrawal symptoms.

A new isotonic energy drink called COMBAT COOLER is being developed for inclusion in the North Atlantic Treaty Organization (NATO) Meal, Ready-to-Eat (MRE) produced for soldiers by Nautilus GmbH Laboratoriumsbedarf & Co. KG.

Nautilus' VitRx over-the-counter medicated chewing-gum could be a new tool to block the spread of COVID-19. VitRx is infused with a plant-based enzyme that acts like flypaper to trap the virus, plus blocks the receptor binding domain.